StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a report issued on Saturday morning. The brokerage issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
Genocea Biosciences has a 1 year low of $0.00 and a 1 year high of $0.00. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.35 and a current ratio of 1.35. The company has a market capitalization of $6,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.61.
About Genocea Biosciences
Further Reading
- Five stocks we like better than Genocea Biosciences
- Breakout Stocks: What They Are and How to Identify Them
- Palantir Cracks $50, Is There Still Time to Get on Board?
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Insider Buying Signals Upside for These 3 Stocks
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
